In the biopharma world, the gold standard for evidence has always been the randomized controlled trial (RCT). It’s clean, controlled, and designed to answer a specific question. But what happens after a drug is approved? How does it perform in the messy, unpredictable real world with diverse patient populations and comorbidities? This is where a new kind of data comes into play.

This raw information is called Real-World Data (RWD). It’s the puzzle pieces. When you collect, curate, and analyze RWD to generate clinical insights, you create Real-World Evidence (RWE). Think of RWD as the raw ingredients (flour, eggs, sugar) and RWE as the finished cake (the evidence that answers a question about health outcomes). As a sales professional, understanding this distinction is key. You're not just selling access to data; you're selling the potential for powerful, evidence-based insights.

The foundation of RWE is built on data collected during routine patient care. These primary sources offer a direct window into the patient journey.

EHRs are incredibly rich, containing physician notes, lab results, diagnoses, and treatment plans. This provides deep clinical granularity. However, the data can be unstructured (like free-text notes) and inconsistent across different hospital systems, making it challenging to aggregate and analyze.

Claims data is another cornerstone. This is the information generated for billing purposes when a patient receives care. It tells you what services were provided, where, and when. It's highly structured and covers large populations, making it excellent for understanding treatment patterns and costs at scale. The trade-off? It lacks clinical detail. A billing code can tell you a patient has diabetes, but it won't tell you their blood sugar levels or lifestyle factors.

Patient registries are organized systems that use observational methods to collect uniform data on a population defined by a particular disease, condition, or exposure. A registry for cystic fibrosis, for instance, collects specific, high-quality data directly relevant to that condition over a long period. This makes them powerful for studying disease progression and the long-term effects of treatments, though their scope is often limited to a single disease area.

Beyond the core sources, a wave of new data is enriching the RWE landscape. Pharmacy and laboratory data provide specific insights into medication adherence and biomarker levels. Genomic data, once purely a research tool, is now increasingly part of routine care, linking genetic profiles to treatment outcomes.

Perhaps the most dynamic new sources are from wearable devices and mobile apps. Smartwatches, fitness trackers, and patient-facing apps can capture continuous data on activity levels, heart rate, sleep patterns, and patient-reported outcomes directly from the source. This offers a minute-by-minute view of a patient's health outside of the clinic. The challenge lies in data quality, patient privacy, and integrating this torrent of information into a cohesive analysis.

No single RWD source is perfect. Each has inherent biases and limitations. The true power of RWE comes from linking different datasets together. For example, linking claims data with EHR data can provide both scale and clinical depth. This process of curation, standardization, and linkage is what transforms raw, messy RWD into the analysis-ready asset that powers AI platforms and delivers actionable insights for your clients' commercial strategies.

Ready to test your knowledge?

Understanding these data sources is the first step. Next, we'll explore how this evidence is applied to solve real challenges in the biopharma industry.